Stanford scientists regrow lost cartilage and reverse arthritis in major breakthrough

A recent Stanford Medicine-led study has unveiled a significant breakthrough in treating arthritis by targeting a protein linked to aging. Researchers successfully restored lost knee cartilage in older mice and prevented arthritis development after joint injuries. The treatment, which blocks a protein called 15-PGDH, also showed promising results in human tissue samples collected during knee replacement surgeries, prompting them to produce new, functional cartilage. This innovative approach raises the possibility of repairing damaged cartilage caused by aging or osteoarthritis through local injections or oral medication, potentially reducing the need for knee and hip replacement surgeries. An oral version of this treatment is already undergoing clinical trials for age-related muscle weakness. Osteoarthritis, affecting approximately one in five U.S. adults, is a debilitating condition that gradually breaks down joint cartilage, causing pain, stiffness, and swelling. Current treatments primarily offer pain relief or necessitate joint replacement, as no approved medication can slow, stop, or reverse the underlying disease process. The new treatment works by inhibiting 15-PGDH, a "gerozyme" that becomes more abundant with age and contributes to tissue decline. Unlike other tissues, cartilage regeneration appears to involve chondrocytes shifting their gene activity to a more youthful state, rather than relying on stem cells. This novel method of regenerating adult tissue holds substantial clinical promise for addressing arthritis.